Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$88.74 USD

88.74
1,093,175

+4.62 (5.49%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (214 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

by Zacks Equity Research

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

BD's (BDX) New FDA Approval to Improve MRSA Diagnostics

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.

Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays

by Zacks Equity Research

Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.

LabCorp (LH) Expands Laboratory Relationship With New Pact

by Zacks Equity Research

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y

by Zacks Equity Research

NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists

by Zacks Equity Research

For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

by Zacks Equity Research

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets

by Zacks Equity Research

Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.

Abbott's (ABT) New Pact to Advance Clinical Trials Diversity

by Zacks Equity Research

Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.